2021 Hurun China Top 500 Freshly Released!

Recently, the Hurun Research Institute released the "2021 Hurun China Top 500".
All selected are Chinese non-state-owned enterprises, and they are ranked according to the company's market value or valuation
.
The market value of listed companies is calculated based on the closing price on November 19, 2021, and the valuation of non-listed companies is estimated with reference to listed companies in the same industry or based on a new round of financing
.
Judging from the list, there are a large number of companies in the pharmaceutical industry on the list, of which 10 are in the top 100, including Mindray Medical, WuXi AppTec, WuXi Biologics, Hengrui Medicine, Aier Ophthalmology, BeiGene, Zhizhi Fei Biology, Yangzijiang Pharmaceutical, Wantai Biopharmaceutical, Kanglong Chemical,
etc.
Mindray Medical ranked 17th overall Mindray Medical performed very well, ranking 17th overall, with a value of 460 billion yuan
.
According to the 2021 third quarterly report previously released by Mindray Medical, the company achieved revenue of 19.
392 billion yuan in the first three quarters of 2021, a year-on-year increase of 20.
72%; net profit attributable to the parent was 6.
663 billion yuan, a year-on-year increase of 24.
23%
.
Mindray Medical has attracted much market attention.
In recent years, institutions have gathered to investigate the company.
On January 4, 2022, Mindray Medical announced that the company had received a total of 1,270 participants from 649 institutions for research and roadshow activities in two months
.
There are many leading large-scale public offerings, private placements, securities companies, banks, insurance companies, overseas institutions, etc.
participating institutions
.
Among them, only on October 20, 2021, the record form of investor relations activities released by Mindray Medical showed that 1,107 personnel from more than 600 institutions participated in the survey
.
According to the company's "Investor Relations Activity Record Form" on January 17, 2022, the company's domestic medical new infrastructure projects in 2021 are progressing smoothly, and the expected orders have been placed by the end of 2021.
From the perspective of the company's accessible market, the current domestic New medical infrastructure business opportunities have reached 20 billion yuan
.
At the same time, with the release of policies such as the "Thousand-County Project", the market demand for county-level hospitals is expected to further increase
.
According to the company's statistics, from the perspective of Mindray Medical's accessible market, the business opportunities brought by the "Thousand County Project" in the next few years are expected to reach 10 billion yuan
.
From the perspective of the industry, the domestic medical device industry is ushering in a stage of rapid development
.
In the short term, giant companies are expected to continue to benefit from import substitution in the field of new domestic infrastructure and high-end products, as well as growth in overseas market demand; in the medium and long term, domestic giants with efficient R&D and strong channel management capabilities are expected to gain more.
many development opportunities
.
The medical device industry has achieved amazing growth in recent years
.
Mindray Medical, a domestic medical device company on the list, also shows us the rapid increase in the strength of Chinese medical device companies
.
In the future, high-quality machinery companies like Mindray that have long insisted on R&D investment and perfected the construction of technical teams may have more development prospects
.
CXO companies performed well.
WuXi PharmaTech and WuXi Biologics followed Mindray Medical, with a value of 385 billion yuan, tied for 23rd
.
In 2021, the CXO industry has also achieved good development, showing a trend of high prosperity, and the strong enterprises with core competitiveness such as technology and integration have been strong, and their performance has been greatly increased
.
WuXi AppTec is a company that provides integrated, end-to-end new drug R&D and production services for the biopharmaceutical industry, with operating bases in Asia, Europe, and North America
.
On January 19, WuXi AppTec released the 2021 annual performance forecast.
During the reporting period, the company is expected to achieve revenue of 22.
819 billion yuan to 22.
902 billion yuan, a year-on-year increase of 38%-38.
5%; net profit of 4.
973 billion yuan to 5.
032 billion yuan, year-on-year.
An increase of 68%-70%
.
Regarding the reasons for the pre-increase in performance, WuXi AppTec said that the company has always implemented the strategy of "following molecules", and the integrated chemical business (WuXi Chemistry) segment will continue to build an "integrated, end-to-end" CRDMO (Contract Research, Development and Development) and production organization) business, the demand for orders is strong, which will promote the accelerated growth of the company's full-year sales in 2021
.
WuXi Biologics is a CDMO enterprise featuring an open, integrated biopharmaceutical capability and technology empowerment platform.
The company can provide end-to-end R&D services for biopharmaceutical companies and biotechnology companies, from concept to commercial production.
the whole process
.
At the recent JPM meeting, WuXi Biologics reported that this year's revenue is expected to be around 9.
8 billion yuan, with a CAGR of 62% in the past five years.

.